Upgrade to SI Premium - Free Trial

Leerink Partners Downgrades Sarepta Therapeutics (SRPT) to Market Perform

July 21, 2025 3:23 AM
Leerink Partners analyst Mani Foroohar downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform to Market Perform with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades

Next Articles